Hannan Nicholas R F, Sampaziotis Fotios, Segeritz Charis-Patricia, Hanley Neil A, Vallier Ludovic
1 Anne McLaren Laboratory for Regenerative Medicine, Department of Surgery, Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge , Cambridge, United Kingdom .
2 Faculty of Medical and Human Sciences, Centre for Endocrinology and Diabetes, Manchester Academic Health Sciences Centre, Institute of Human Development, University of Manchester , Manchester, United Kingdom .
Stem Cells Dev. 2015 Jul 15;24(14):1680-90. doi: 10.1089/scd.2014.0512. Epub 2015 Apr 15.
Collectively, lung diseases are one of the largest causes of premature death worldwide and represent a major focus in the field of regenerative medicine. Despite significant progress, only few stem cell platforms are currently available for cell-based therapy, disease modeling, and drug screening in the context of pulmonary disorders. Human foregut stem cells (hFSCs) represent an advantageous progenitor cell type that can be used to amplify large quantities of cells for regenerative medicine applications and can be derived from any human pluripotent stem cell line. Here, we further demonstrate the application of hFSCs by generating a near homogeneous population of early pulmonary endoderm cells coexpressing NKX2.1 and FOXP2. These progenitors are then able to form cells that are representative of distal airway epithelium that express NKX2.1, GATA6, and cystic fibrosis transmembrane conductance regulator (CFTR) and secrete SFTPC. This culture system can be applied to hFSCs carrying the CFTR mutation Δf508, enabling the development of an in vitro model for cystic fibrosis. This platform is compatible with drug screening and functional validations of small molecules, which can reverse the phenotype associated with CFTR mutation. This is the first demonstration that multipotent endoderm stem cells can differentiate not only into both liver and pancreatic cells but also into lung endoderm. Furthermore, our study establishes a new approach for the generation of functional lung cells that can be used for disease modeling as well as for drug screening and the study of lung development.
总体而言,肺部疾病是全球过早死亡的主要原因之一,也是再生医学领域的一个主要研究重点。尽管取得了重大进展,但目前在肺部疾病的细胞治疗、疾病建模和药物筛选方面,只有少数干细胞平台可用。人前肠干细胞(hFSCs)是一种优势祖细胞类型,可用于扩增大量细胞以用于再生医学应用,并且可以从任何人类多能干细胞系中获得。在这里,我们通过生成共表达NKX2.1和FOXP2的早期肺内胚层细胞的近乎同质群体,进一步证明了hFSCs的应用。然后,这些祖细胞能够形成代表远端气道上皮的细胞,这些细胞表达NKX2.1、GATA6和囊性纤维化跨膜传导调节因子(CFTR)并分泌SFTPC。这种培养系统可应用于携带CFTR突变Δf508的hFSCs,从而能够开发出一种囊性纤维化的体外模型。该平台与小分子的药物筛选和功能验证兼容,这些小分子可以逆转与CFTR突变相关的表型。这是首次证明多能内胚层干细胞不仅可以分化为肝脏和胰腺细胞,还可以分化为肺内胚层。此外,我们的研究建立了一种生成功能性肺细胞的新方法,可用于疾病建模以及药物筛选和肺发育研究。